Supplementary Materials from Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

SUPPLEMENTARY TABLES Supplementary Table 1. Treatment-emergent grade 3/4 adverse events in the safety population (n=116) Supplementary Table 2. MEDI3617 pharmacokinetic parameters Supplementary Table 3. Treatment outcome: objective response and progression-free survival, by cohort